These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 27716320)

  • 1. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
    Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N
    Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.
    Cipriani P; Di Benedetto P; Ruscitti P; Capece D; Zazzeroni F; Liakouli V; Pantano I; Berardicurti O; Carubbi F; Pecetti G; Turricchia S; Alesse E; Iglarz M; Giacomelli R
    J Rheumatol; 2015 Oct; 42(10):1808-16. PubMed ID: 26276964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
    Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
    Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.
    Cutolo M; Montagna P; Brizzolara R; Smith V; Alessandri E; Villaggio B; Sulli A; Tavilla PP; Pizzorni C; Soldano S
    J Rheumatol; 2015 Mar; 42(3):456-63. PubMed ID: 25593238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.
    Serratì S; Chillà A; Laurenzana A; Margheri F; Giannoni E; Magnelli L; Chiarugi P; Dotor J; Feijoo E; Bazzichi L; Bombardieri S; Kahaleh B; Fibbi G; Del Rosso M
    Arthritis Rheum; 2013 Jan; 65(1):258-69. PubMed ID: 22972461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells.
    Romano E; Rosa I; Fioretto BS; Giuggioli D; Manetti M; Matucci-Cerinic M
    Rheumatology (Oxford); 2023 Feb; 62(SI):SI125-SI137. PubMed ID: 35900177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells.
    Mazzotta C; Manetti M; Rosa I; Romano E; Blagojevic J; Bellando-Randone S; Bruni C; Lepri G; Guiducci S; Ibba-Manneschi L; Matucci-Cerinic M
    Arthritis Res Ther; 2017 Feb; 19(1):27. PubMed ID: 28183357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT).
    Abu El-Asrar AM; De Hertogh G; van den Eynde K; Alam K; Van Raemdonck K; Opdenakker G; Van Damme J; Geboes K; Struyf S
    Exp Eye Res; 2015 Mar; 132():179-89. PubMed ID: 25637870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells.
    Soldano S; Paolino S; Pizzorni C; Trombetta AC; Montagna P; Brizzolara R; Corallo C; Giordano N; Sulli A; Cutolo M
    Clin Exp Rheumatol; 2017; 35(3):484-493. PubMed ID: 28134077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis.
    Corallo C; Franci B; Lucani B; Montella A; Chirico C; Gonnelli S; Nuti R; Giordano N
    Int J Immunopathol Pharmacol; 2015 Mar; 28(1):93-103. PubMed ID: 25816411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.
    Manetti M; Guiducci S; Romano E; Ceccarelli C; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
    Circ Res; 2011 Jul; 109(3):e14-26. PubMed ID: 21636803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transdifferentiation of fibroblasts into myofibroblasts in the skin lesion of systemic sclerosis: role of transforming growth factor β1 and its signal transduction].
    Liu T; Hu XD
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1840-5. PubMed ID: 22126761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis.
    Liu T; Zhang J; Zhang J; Mu X; Su H; Hu X; Liu W; Zhao E; Li W
    PLoS One; 2013; 8(4):e60414. PubMed ID: 23577108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
    Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.
    Mendoza FA; Piera-Velazquez S; Farber JL; Feghali-Bostwick C; Jiménez SA
    Arthritis Rheumatol; 2016 Jan; 68(1):210-7. PubMed ID: 26360820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis.
    Rosa I; Romano E; Fioretto BS; El Aoufy K; Bellando-Randone S; Matucci-Cerinic M; Manetti M
    Cells; 2023 Sep; 12(17):. PubMed ID: 37681927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
    Cutolo M; Ruaro B; Montagna P; Brizzolara R; Stratta E; Trombetta AC; Scabini S; Tavilla PP; Parodi A; Corallo C; Giordano N; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
    Arthritis Res Ther; 2018 May; 20(1):77. PubMed ID: 29720235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone morphogenetic protein-7 inhibits endothelial-to-mesenchymal transition in primary human umbilical vein endothelial cells and mouse model of systemic sclerosis via Akt/mTOR/p70S6K pathway.
    Shen C; Jiang Y; Li Q; Liu C; Hu F; Li M
    J Dermatol Sci; 2021 Aug; 103(2):82-92. PubMed ID: 34266726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.